Uzbekistan, Chinese Biopharma Giant Walvax Discuss Plans to Launch Local Vaccine Production

During an official visit to China, a delegation from Uzbekistan has met with Walvax Biotechnology Co., Ltd, a leading Chinese biopharmaceutical company, to discuss establishing local vaccine production in Uzbekistan.

Walvax, established in 2001, boasts a portfolio of nine registered vaccines including those targeting pneumococcal disease (PCV13), human papillomavirus (HPV2), and meningococcal infection, The Caspian Post reports, citing Uzbek media.

With an annual production capacity of up to 390 million doses, Walvax distributes widely across China and exports to 18 countries.

The Uzbek delegation, comprising officials from the Ministry of Health, the Pharmaceutical Industry Development Agency, and the Center for Pharmaceutical Products Safety, focused discussions on establishing local vaccine production in Uzbekistan, technology transfer, product registration, and selecting reliable partners for collaborative projects.

Walvax expressed strong interest in a sustainable partnership, prioritizing local manufacturing, stable domestic supply, and expansion into Central Asian and CIS markets.

Both sides committed to deepening cooperation and agreed on regular information exchanges. This partnership is anticipated to significantly advance Uzbekistan’s pharmaceutical sector and bolster its national healthcare system.